Loading
Life sciences · Journal article
Memo - Magazine of European Medical Oncology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Summary The treatment algorithm for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) is rapidly evolving, as shown by the approval of three new agents in 2025: inavolisib, imlunestrant and datopotamab-deruxtecan. Endocrine therapy (ET) is the cornerstone of systemic treatment, while chemotherapy is generally reserved for later lines of treatment, particularly since the combination of ET and CDK4/6 inhibitors has shown remarkable efficacy in the first-line setting, outperforming both single agent and polychemotherapy. Improved understanding of the mechanisms underlying endocrine resistance, including aberrant activation of the PI3K/AKT/mTOR pathway and acquired ESR1 gene mutations, has led to the development and integration of targeted agents into the treatment landscape of HR-positive, HER2-negative MBC. The PIK3CA inhibitor inavolisib, in combination with palbociclib and fulvestrant, has been established as a new treatment standard for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative MBC. Likewise, the oral selective estrogen receptor degrader (SERD) imlunestrant has broadened treatment options for patients with ESR1-mutated disease, after progression on ET, regardless of prior CDK4/6 inhibitor exposure. Antibody–drug conjugates (ADCs) have also reshaped the therapeutic landscape, progressively replacing conventional chemotherapy and shifting its use to later lines of treatment. Together with trastuzumab-deruxtecan and sacituzumab-govitecan, datopotamab-deruxtecan has become the third ADC approved for the treatment of patients with HR-positive, HER2-negative MBC. Collectively, these advances reflect a dynamic and rapidly expanding treatment landscape. However, optimal sequencing strategy remains undefined. This short review aims to provide an overview of the three recently approved agents and offers a glimpse into future therapeutic strategies for HR-positive, HER2-negative MBC.